It is really unclear that the tenofovir disoproxil fumurate and entecavir differ in their association with the risk of hepatocellular carcinoma in patients with chronic hepatitis B and previous meta-analyses. Therefore, an attempt was made to ensure that a solution is provided to the otherwise conflicting conclusions with a substantial amount of heterogeneity. The PubMed, Embase, Web of Science, and other allied sources have been in the position to provide for the best possible care and hence, has conducted the covariate studies and hence, it was unraveled that the adjusted hazard ratios for the healthy maintenance of the hepatocellular carcinoma especially in the patients who have been suffering from hepatitis B. this has already been registered with PROSPERO. There have been 31 studies that have been conducted so far in order to unravel the cumulative incidence of tenofovir. However, it has been associated with the administrative database and research which dwindles between the two regimes and databases in the ratio of 0.5-.10 mg/L. Therefore, an attempt has been, made to provide the best possible care to these kinds of patients and hence, for this an additional research should be carried to substantiate the claim.
Ref art: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30249-1/fulltext
